CV Therapeutics Announces Four Abstracts Accepted for Presentation at American College of Cardiology Scientific Sessions 2006
March 03 2006 - 4:30PM
PR Newswire (US)
PALO ALTO, Calif., March 3 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that four
abstracts have been accepted for presentation at the American
College of Cardiology (ACC) Scientific Sessions 2006, taking place
in Atlanta, GA from March 11-14, 2006. Accepted abstracts include:
-- Ranolazine Safety and Tolerability During Long-Term Treatment of
Stable Angina. Tuesday, March 14, 2006 from 10:00 a.m. to 11:00
a.m. Eastern Time (ET), Hall B1, Georgia World Congress Center.
Poster Session # 999-253. -- Better Ventricular Function and
Reduced Necrosis After Myocardial Ischemia/Reperfusion in Rabbits
Treated With Ranolazine, an Inhibitor of the Late Sodium Current.
Sunday, March 12, 2006 from 2:30 p.m. to 3:30 p.m. ET, Hall B1,
Georgia World Congress Center. Poster Session # 927-216. -- African
Americans With Chronic Angina: Risk Factors and Treatment Profiles
Compared to Caucasians. Tuesday, March 14, 2006 from 7:15 a.m. to
7:30 a.m. ET, Room B405, Georgia World Congress Center. Oral
Abstract # 836-4. -- Hydrogen Peroxide-Induced Arrhythmogenic
Activity and Contractile Dysfunction of Ventricular Myocytes Is
Reduced by a Blocker of Late Sodium Current. Sunday, March 12, 2006
from 11:00 a.m. to 12:00 p.m. ET, Hall B1, Georgia World Congress
Center. Poster Session # 901-130. Additional information regarding
the ACC Scientific Sessions 2006 can be accessed at
http://www.acc.org/2006ann_meeting/home/home.htm About CV
Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto,
California, is a biopharmaceutical company focused on applying
molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics' approved products
include Ranexa(TM) (ranolazine extended-release tablets) and
ACEON(R) (perindopril erbumine) Tablets. Ranexa is indicated for
the treatment of chronic angina in patients who have not achieved
an adequate response with other antianginal drugs, and should be
used in combination with amlodipine, beta-blockers or nitrates. In
addition, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor,
for reduction of the risk of cardiovascular mortality or nonfatal
myocardial infarction in patients with stable coronary artery
disease and treatment of essential hypertension. CV Therapeutics
also has other clinical and preclinical drug development candidates
and programs, including regadenoson, which is being developed for
potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies. Regadenoson has not been approved for
marketing by any regulatory authorities. Except for the historical
information contained herein, the matters set forth in this press
release, including statements as to development, clinical studies,
special protocol assessment agreements, regulatory review and
approval, and commercialization of products, are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially, including,
early stage of development; regulatory review and approval of our
products; special protocol assessment agreements; the conduct and
timing of clinical trials; commercialization of products; market
acceptance of products; product labeling; and other risks detailed
from time to time in CV Therapeutics' SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended September 30,
2005. CV Therapeutics disclaims any intent or obligation to update
these forward-looking statements. DATASOURCE: CV Therapeutics, Inc.
CONTACT: Investors: Christopher Chai, Vice President, Treasury and
Investor Relations, +1-650-384-8560, or Media: John Bluth, Senior
Director, Corporate Communications, +1-650-384-8850, both of CV
Therapeutics, Inc. Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024